1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. KINIKSA PHARMACEUTICALS LTD - ORDINARY SHARES - CLASS A
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A
XNAS: KNSA
Mid-range Performer
Download real time
76.310.52(0.69%)
116.79% Gain from 52W Low
391.5K
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Kiniksa Pharma Ltd (Class A) quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Kiniksa Pharma Ltd (Class A) share price target, revenues, EPS, net income and more

Kiniksa Pharma Ltd (Class A) quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Kiniksa Pharma Ltd (Class A) Jun-2026 Quarterly Revenue is $244 Million which is growth of 55.4% YoY.

  • POSITIVE

    Quarterly Net Profit Kiniksa Pharma Ltd (Class A) Jun-2026 Quarterly Net Profit is $25 Million which is growth of 42.6% YoY.

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
243.6214.3202.1180.9156.8137.8122.5112.2108.679.983.467.171.5
Cost Of Rev.
111.696.49183.67161.766.149.442.331.426.526.421.7
Gross Profit
132117.9111.297.385.876.156.562.866.348.556.940.749.8
⌄
104.888.691.473.365.662.975.872.566.46556.851.652.9
Operating Profit
27.229.319.82420.213.3-19.3-9.7-0.1-16.50.1-10.9-3.2
⌄
-------------
Profit Before Tax
31.132.723.327.222.915.6-17-7.22.3-14.32.5-8.5-1.2
Tax
5.710.19.18.757-8.15.56.23.4-22.85.4-16.2
⌄
25.422.614.218.417.88.5-8.9-12.7-3.9-17.725.2-13.915
Diluted NI Avail to Com Stockholders Ann.
25.422.614.218.417.88.5-8.9-12.7-3.9-17.725.2-13.915
Basic EPS
0.30.30.20.30.20.1-0.1-0.2-0.1-0.30.4-0.20.2
Diluted EPS After ExtraOrdinary
0.30.30.20.20.20.1-0.1-0.2-0.1-0.30.4-0.20.2
Number Of Shares End
77.676.57674.773.472.772.371.77170.670.470.269.9
Net Income Continuing Discontinued Operations
25.422.614.218.417.88.5-8.9-12.7-3.9-17.725.2-13.915
Normalized Income
25.422.614.218.417.88.5-8.9-12.7-3.9-17.725.2-13.915
Interest Income
-------------
Interest
-------------
Net Interest Income
-------------
EBIT
27.229.319.82420.213.3-19.3-9.7-0.1-16.50.1-10.9-3.2
EBITDA
27.729.720.224.420.513.6-18.9-9.30.3-16.10.6-10.3-2.6
Reconciled Cost Of Rev.
111.696.49183.67161.766.149.442.331.426.526.421.7
Reconciled Depr.
0.50.50.50.40.40.30.40.40.40.50.50.60.6
Profit From Continuing Operations
25.422.614.218.417.88.5-8.9-12.7-3.9-17.725.2-13.915
Normalized EBITDA
27.729.720.224.420.513.6-18.9-9.30.3-16.10.6-10.3-2.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Kiniksa Pharma Ltd (Class A) competitor comparison and performance snapshot within industry

Kiniksa Pharma Ltd (Class A) annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Kiniksa Pharma Ltd (Class A) Dec-2025 Annual Revenue is $678 Million which is growth of 60.1% YoY.

  • POSITIVE

    Annual Net Profit Kiniksa Pharma Ltd (Class A) Dec-2025 Annual Net Profit is $59 Million which is growth of 236.6% YoY.

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
45.5%
-
 677.6423.2270.3220.238.5
Cost Of Rev. Ann.
87%
-
382.6307.2189.289.9479.9-----
Gross Profit Ann.
28.8%
-
458.3370.4234180.3173.228.6-----
Operating Exp. Ann.
21.5%
13.2%
358293.1279.6205.5163.4185.2157.4170108.265.424
Operating Profit Ann.
99%
-
100.377.2-45.6-25.29.8-156.6-157.4-170-108.2-65.4-24
⌄
-
-
 ---1.30.11.16.14.70.50.1
Other Exp. Ann.
-
-
 11.79.58.5-------
PBT Ann.
100.7%
-
114.388.9-36.2-16.711-156.5-156.2-163.9-103.4-64.9-23.9
Tax Ann.
-
41.9%
33.629.97-30.7-172.31.45.2-2.1-0.20
⌄
-31.5%
-
80.759-43.214.1183.4-157.9-161.4-161.9-103.2-64.9-24
Diluted NI Avail to Com Stockholders Ann.
-31.5%
-
80.759-43.214.1183.4-157.9-161.4-161.9-103.2-64.9-24
EPS Ann.
-32.5%
-
 0.8-0.60.22.6-2.3-2.6-3-3.5-2.7-0.7
Diluted EPS Ann.
-32.5%
-
 0.8-0.60.22.6-2.3-2.6-3-3.5-2.7-0.7
Number Of Shares End
3%
2.2%
 7672.370.469.66968.154.949.532.5-
Total Exp. Ann.
41.8%
30.7%
 600.3468.9295.5210.4195.2157.4170108.265.424
Net Income Continuing Discontinued Operations Ann.
-31.5%
-
80.759-43.214.1183.4-157.9-161.4-161.9-103.2-64.9-24
Normalized Income Ann.
-31.5%
-
80.759-43.214.1183.4-157.9-161.4-161.9-103.2-64.9-24
Interest Income Ann.
-
-
 ---1.30.11.16.14.70.50.1
Interest Ann.
-
-
 ----------
EBITDA Ann.
86.2%
-
10278.8-43.9-22.912.2-154.3-155-167.9-107.9-65.4-24
Reconciled Cost Of Rev. Ann.
87%
-
382.6307.2189.289.9479.9-----
Reconciled Depr. Ann.
-12.6%
-7.8%
1.81.61.72.32.42.42.42.10.300
Profit From Continuing Operations Ann.
-31.5%
-
80.759-43.214.1183.4-157.9-161.4-161.9-103.2-64.9-24
Normalized EBITDA Ann.
86.2%
-
10278.8-43.9-22.912.2-154.3-155-167.9-107.9-65.4-24
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
60.1%
2Y CAGR
58.3%
3Y CAGR
45.5%
Net Profit Ann.
2Y CAGR
104.6%
3Y CAGR
-31.5%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
4.8%
2Y CAGR
19.4%
3Y CAGR
21.5%
5Y CAGR
13.2%
7Y CAGR
15.3%
Operating Expenses Annual Cr growth is lower than historical averages.

Kiniksa Pharma Ltd (Class A) balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Kiniksa Pharma Ltd (Class A) Dec-2025 Total Shareholders Fund is $568 Million which is growth of 29.5% YoY.

  • POSITIVE

    Total Assets Kiniksa Pharma Ltd (Class A) Dec-2025 Total Assets is $764 Million which is growth of 31.5% YoY.

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
18.4%
16.9%
763.6580.6526.3459.7232.8349.5254.532247.556.5
⌄
45.6%
39.2%
196142.187.563.547.837.529.142.7137.282.2
⌄
12.7%
12.7%
567.6438.4438.8396.2185311.9225.4279.3-89.7-25.7
Total Capitalization Ann.
12.7%
12.7%
567.6438.4438.8396.2185311.9225.4279.3-89.7-25.7
Tangible Assets Ann.
13.5%
12.1%
552.4422.2421.6377.9165.8311.9225.4279.3-89.7-25.7
Working Capital Ann.
25.6%
5.2%
388231.2212.6196151.6301.4213.8271.229.754
Invested Capital Ann.
12.7%
12.7%
567.6438.4438.8396.2185311.9225.4279.3-89.7-25.7
Tangible Book Value Ann.
13.5%
12.1%
552.4422.2421.6377.9165.8311.9225.4279.3-89.7-25.7
Borrowings Ann.
17.2%
6.3%
9.59.912.35.96.172.7---
Net Debt Ann.
-
-
----------
Share Issued Ann.
3.1%
2.3%
76.372.570.569.769.168.254.949.54747
Number Of Shares End
3%
2.2%
7672.370.469.66968.154.949.532.5-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
31.5%
2Y CAGR
20.5%
3Y CAGR
18.4%
5Y CAGR
16.9%
7Y CAGR
13.1%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
38.4%
2Y CAGR
47.8%
3Y CAGR
43.5%
5Y CAGR
34.3%
7Y CAGR
18.4%
Total Current Liabilities Annual Cr growth is stable compared to historical averages.
Total ShareHolders Funds Ann.
1Y CHG
29.5%
2Y CAGR
13.7%
3Y CAGR
12.7%
5Y CAGR
12.7%
7Y CAGR
10.7%
Total ShareHolders Funds Annual growth is higher than historical averages.

Kiniksa Pharma Ltd (Class A) ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Kiniksa Pharma Ltd (Class A) Book Value Per Share is $8 which is growth of 25.5% YoY.

  • NEUTRAL

    ROE Kiniksa Pharma Ltd (Class A) ROE is 0% which is growth of 0% YoY.

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
RoA Ann. %
-
-
--7.80%2.86%52.96%-54.24%-53.44%-56.16%-55.88%-124.80%-42.45%
ROE Ann. %
-
-
--9.85%3.37%63.10%-63.55%-60.06%-64.15%-108.91%--
ROIC %
-
-
--25.81-17.7-15.8-13.5-14.7--
OPM Ann. %
36.9%
-
11.40%-10.78%-9.32%4.44%-406.38%-----
Inventory Turnover Ratio Ann.
-
-
-6.63.43.72.7-----
Asset Turnover Ann. %
-
-
-0.80.60.60.1-----
Working Capital Turnover Ann.
17.8%
-
1.81.81.31.10.3
Quick Ratio Ann.
-
-
-2.83.64.54.210.28.47.22.624.3
Current Ratio Ann.
-
-
-3.34.35.24.410.58.77.42.724.5
Interest Coverage Ratio Ann.
-
-
----------
LT Debt To Equity Ann.
-
-
-00000---
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Kiniksa Pharma Ltd (Class A) cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Kiniksa Pharma Ltd (Class A) Dec-2025 Cash From Operating Activity is $138 Million which is growth of 437.1% YoY.

  • NEGATIVE

    Net Cash Flow Kiniksa Pharma Ltd (Class A) Dec-2025 Net Cash Flow is $-18 Million which is growth of -123.8% YoY.

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16
⌄
187.6%
-
13825.713.35.8-126.3-136.5-158.4-81-50.2-21.9
⌄
-
-
-18937.7-29.6-8.1128.6-23.449.2-239.2-0.1
⌄
136.3%
-32%
3312.31.52.55.9227.184.1346.739.942.5
Cash Plus Cash Eqv. End Of Year Ann.
10.5%
7.7%
165.6183.6108122.7122.5114.347.172.245.756.1
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-1875.6-14.80.28.267.1-25.126.5-10.420.6
Cash Plus Cash Eqv. Begin Of Year Ann.
14.4%
31.3%
183.6108122.7122.5114.347.172.245.756.135.4
Income Tax Paid Supplemental Data Ann.
-34.5%
43.1%
325.610.71.30.51.70.40.30.1
Interest Paid Supplemental Data Ann.
-
-
----------
Capex Ann.
-
-
-1.6-0.3-0.1-0.1-20.4-0.3-3.2-5.3-0.1
Issuance Of Capital Stock Ann.
-
-
---3.4221.783.135039.942.5
Issuance Of Debt Ann.
-
-
----------
Repayment Of Debt Ann.
-
-
----------
Repurchase Of Capital Stock Ann.
-
-
-7.7-5-2.2-0.9------
Free Cash Flow Ann.
188.2%
-
136.425.413.25.7-146.7-136.8-161.6-86.3-50.3-21.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
437%
2Y CAGR
222.1%
3Y CAGR
187.6%
Cash from Operating Activity Annual growth is higher than historical averages.
Cash from Financing Act. Ann.
1Y CHG
168.3%
2Y CAGR
369%
3Y CAGR
136.3%
5Y CAGR
-32%
7Y CAGR
-28.5%
Cash from Financing Annual Activity growth is higher than historical averages.
×